Theratechnologies Inc. (NASDAQ:THTX) Sees Large Increase in Short Interest

Theratechnologies Inc. (NASDAQ:THTX) was the recipient of a significant increase in short interest in the month of December. As of December 15th, there was short interest totalling 72,200 shares, an increase of 64.8% from the November 30th total of 43,800 shares. Currently, 0.4% of the shares of the company are sold short. Based on an average trading volume of 72,500 shares, the days-to-cover ratio is currently 1.0 days.

Theratechnologies Stock Performance

Shares of THTX traded down $0.04 during midday trading on Friday, hitting $1.79. 100,697 shares of the stock traded hands, compared to its average volume of 52,512. The business’s 50 day moving average price is $1.38 and its two-hundred day moving average price is $1.35. The firm has a market capitalization of $82.30 million, a PE ratio of -17.90 and a beta of 1.42. Theratechnologies has a 1-year low of $1.08 and a 1-year high of $2.58.

Theratechnologies (NASDAQ:THTX) last announced its earnings results on Thursday, October 10th. The company reported $0.06 earnings per share for the quarter, beating the consensus estimate of $0.03 by $0.03. The business had revenue of $22.60 million for the quarter. During the same quarter in the prior year, the firm earned ($0.03) earnings per share. As a group, equities research analysts forecast that Theratechnologies will post 0.03 EPS for the current fiscal year.

Institutional Investors Weigh In On Theratechnologies

An institutional investor recently raised its position in Theratechnologies stock. National Bank of Canada FI lifted its position in Theratechnologies Inc. (NASDAQ:THTX) by 29.4% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 186,815 shares of the company’s stock after acquiring an additional 42,435 shares during the period. National Bank of Canada FI owned about 0.41% of Theratechnologies worth $232,000 as of its most recent SEC filing.

Theratechnologies Company Profile

Theratechnologies Inc, a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen.